Eagle Pharmaceuticals Inc

EGRX

$15.70

-43.3% last 12 months

Ken Griffin Holding value: $6.18 Million Jim Simons Holding value: $4.09 Million Chuck Royce Holding value: $930 Thousand Steven Cohen Holding value: $31.4 Thousand John Paulson Holding value: $0 Jefferies Group Holding value: $0 First Eagle Investments Holding value: $0 Ken Fisher Holding value: $0 Jeremy Grantham Holding value: $0 Joel Greenblatt Holding value: $0

Market Cap

$198 Million

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$15.04 - $40.85

The lowest and highest price in the last 52 weeks.

Price-Earnings Ratio

16.55x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Compare to
Market
Industry
Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares. $198 Million
Enterprise Value A measure of a company's total value. This includes market cap, cash, and debt. $253 Million
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price. $0.00 (0.0%)
1 Year Return Profit or loss of share price change plus dividend yield. -43.3%
52-Week High Highest share price in the last 52 weeks. $40.85
52-Week Low Lowest share price in the last 52 weeks. $15.04
Beta Beta indicates the volatility of a stock compared to the market. Higher beta means more volatile and thus potentially higher risk and return. 1.01
Outstanding Shares The number of shares the company has issued and are held by stockholders. 13 Million
Avg 30 Day Volume The number of shares traded in the last 30 days. 124 Thousand

Valuation

Compare to
Market
Industry
P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth. 16.55
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued. -10.7
Earnings per Share Earnings divided by outstanding shares. Higher EPS indicates greater value. $0.90
Price to Sales Ratio Market cap divided by the revenue in the most recent year. 0.83
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company 0.83
Enterprise Value to Revenue Enterprise value divided by revenue 0.98
Enterprise Value to EBIT Enterprise Value divided by EBIT 6.16
Total Debt to Enterprise Value Total debt divided by enterprise value 0.28
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary. 0.28

Profitability

Compare to
Market
Industry
Revenue Revenue is the sum of all cash flow into the company. $258 Million
Gross Profit Gross profit is the profit after subtracting the costs of making and selling its products or the costs of providing its services. It indicates the efficiency of using their resources to produce goods or services. $180 Million
EBIT Earnings before tax and interest payments. $41 Million
Net Income Net Income is the profit after all expenses have been deducted from the total revenue. $11.9 Million
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability. 4.64%
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago. -154.6%
Return on Equity Equity divided by market cap. 4.74%
Return on Assets Indicates a company's profitability in relation to its total assets. 2.95%
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits. 12.89%

Insider trades

No purchases

No sells

No purchases

No sells

No purchases

No sells

No purchases

No sells

Q4 2022 Q1 2023 Q2 2023 Q3 2023

About Eagle Pharmaceuticals Inc

CEO: Scott Tarriff

Industry: Pharmaceutical Preparation Manufacturing

Similar stocks

Johnson & Johnson
Johnson & Johnson
GSK Plc - ADR
GSK Plc - ADR
Novartis AG - ADR
Novartis AG - ADR
Teva- Pharmaceutical Industries Ltd. - ADR
Teva- Pharmaceutical Industries Ltd. - ADR
AMGEN Inc.
AMGEN Inc.
Lilly(Eli) & Co
Lilly(Eli) & Co

News

Eagle Pharmaceuticals to Present BYFAVO (remimazolam) for Injection Abstract at Prestigious Society for Neuroscience in Anesthesiology and Critical Care (SNACC) Conference

Eagle Pharmaceuticals to Present BYFAVO (remimazolam) for Injection Abstract at Prestigious Society for Neuroscience in Anesthesiology and Critical Care (SNACC) Conference

-- Abstract compares relative effects on cognitive function following sedation with Byfavo (remimazolam) for injection versus midazolam WOODCLIFF LAKE, N.J.,...

Wallstreet:Online Wallstreet:Online, 26 days ago
Eagle Pharmaceuticals reiterates 2023 adjusted non-GAAP EBITDA

Eagle Pharmaceuticals reiterates 2023 adjusted non-GAAP EBITDA

Eagle Pharmaceuticals Inc (EGRX) Thursday reiterated its previously issued guidance for the 2023 fiscal year.Says full-year 2023 adjusted non-GAAP EBITDA is ...

Seeking Alpha Seeking Alpha, about 1 month ago
Piper Sandler cuts Eagle Pharmaceuticals to underweight post-earnings

Piper Sandler cuts Eagle Pharmaceuticals to underweight post-earnings

Piper Sandler has downgraded Eagle Pharmaceuticals (EGRX) to underweight, citing concerns about the declining contribution of bendamustine products in the lo...

Seeking Alpha Seeking Alpha, about 2 months ago
Eagle Pharmaceuticals, Inc. (EGRX) Q2 2023 Earnings Call Transcript

Eagle Pharmaceuticals, Inc. (EGRX) Q2 2023 Earnings Call Transcript

Eagle Pharmaceuticals, Inc. (NASDAQ:NASDAQ:EGRX) Q2 2023 Earnings Conference Call August 8, 2023 8:30 AM ETCompany ParticipantsLisa Wilson - IRScott Tarriff ...

Seeking Alpha Seeking Alpha, about 2 months ago
Never miss a trade
To improve your user experience we use cookies.